{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.3","upperLimit":"15.3","value":"11.3"},{"comment":"Could not be estimated due to the low number of events disease progression or death.","groupId":"OG001","lowerLimit":"7.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Progression-free survival was defined as the time in weeks from date of first dose until the date of disease progression or death, whichever is earliest.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tisotumab vedotin 0.9 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG000","title":"Part 1: Dose Escalation: Cohort 1 3q4wk 0.9 mg/kg"},{"description":"Tisotumab vedotin 1.2 mg/kg was administered as an intravenous infusion, over a minimum of 30 minutes, 3 times every 4 weeks (3q4wk).","id":"OG001","title":"Part 1: Dose Escalation: Cohort 2 3q4wk 1.2 mg/kg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Baseline to end of follow-up; maximum time of follow-up was 24 weeks","title":"Part 1: Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"weeks"}